Feline Mesenteric Lymph Node Lymphoma (Alimentary Lymphoma – Large Cell)

Feline mesenteric lymph node lymphoma arising as part of large cell (high-grade) alimentary lymphoma (HGAL) is an aggressive malignant neoplasm of lymphocytes, most commonly of T-cell immunophenotype, that primarily involves the gastrointestinal tract and the associated mesenteric lymph nodes. It is distinguished from the more indolent low-grade alimentary lymphoma (LGAL) by its large, pleomorphic neoplastic lymphocytes, rapid clinical progression, and markedly worse prognosis. HGAL, along with intermediate-grade alimentary lymphoma (IGAL), can frequently be diagnosed via cytological evaluation of mesenteric lymph node fine-needle aspirates, without requiring full-thickness surgical biopsies [1]. This subtype represents a clinically urgent diagnosis requiring prompt therapeutic intervention given its aggressive biological behavior.

The precise etiology of feline large cell alimentary lymphoma remains incompletely understood, but several pathogenic factors and mechanisms are recognized:

Immunophenotype and cell of origin: The majority of feline alimentary lymphomas, including the large cell (high-grade) subtype, are of T-cell lineage, arising from mucosal intraepithelial or lamina propria T lymphocytes. The neoplastic transformation leads to the clonal expansion of large, pleomorphic lymphocytes that infiltrate the intestinal wall transmurally and spread readily to the draining mesenteric lymph nodes [1].

Role of chronic intestinal inflammation: Chronic gastrointestinal inflammatory conditions, particularly inflammatory bowel disease (IBD), are hypothesized to create a microenvironment that promotes lymphocyte dysregulation, aberrant antigen stimulation, and eventual malignant transformation. The progression from IBD to LGAL and ultimately to HGAL has been proposed, though causality is not firmly established.

Viral associations: Feline leukemia virus (FeLV) has historically been associated with lymphoma in cats; however, alimentary lymphomas—particularly the T-cell subtypes—occur predominantly in FeLV-negative cats, suggesting that other drivers predominate in this anatomical form.

Paraneoplastic mechanisms: Large cell alimentary T-cell lymphomas can elaborate cytokines and other mediators that cause systemic effects, including marked peripheral eosinophilia, basophilia, hypercalcemia (through PTHrP secretion or cytokine-mediated osteoclast activation), and pyrexia [2]. These paraneoplastic syndromes may precede or accompany the diagnosis and can complicate clinical management.

Rapid progression: The large cell subtype is characterized by a high mitotic index, rapid cellular proliferation, and early dissemination to regional lymph nodes and potentially to other organs (liver, spleen), explaining its aggressive clinical course compared with LGAL [1].

Diagnostic distinction from low-grade disease: Because HGAL and IGAL cells are cytologically distinct from the small lymphocytes of LGAL, mesenteric lymph node fine-needle aspirates are often diagnostic for these high-grade subtypes without requiring surgical full-thickness biopsy—unlike LGAL, which mandates histology for definitive diagnosis [1].

Diagnosis of large cell alimentary lymphoma with mesenteric lymph node involvement relies on a combination of clinical assessment, laboratory evaluation, imaging, and cytological or histological confirmation.

Clinical examination: Abdominal palpation commonly reveals mesenteric lymphadenomegaly, intestinal wall thickening, or a discrete abdominal mass [3]. Generalized poor body condition, muscle wasting, and dehydration are frequent findings.

Laboratory evaluation:

Hematology:

• ·Complete blood count (CBC): Abnormalities are common. Paraneoplastic eosinophilia (elevated eosinophil count) and basophilia have been specifically documented in feline alimentary T-cell lymphoma [2]. Anemia (low HCT/PCV) may be present due to chronic disease, gastrointestinal blood loss, or bone marrow involvement. Lymphocytosis is inconsistent but may occur if neoplastic cells circulate.
• ·WBC: May be elevated with a paraneoplastic granulocytosis; mild-to-moderate leukocytosis has been noted [2].

Serum biochemistry:

• ·Albumin (ALB): Hypoalbuminemia is common due to protein-losing enteropathy (PLE) from intestinal infiltration and malabsorption.
• ·Globulin (GLOB): Variable; may be elevated (inflammatory response) or normal.
• ·Total protein: Often low, mirroring hypoalbuminemia in cases with significant intestinal involvement.
• ·ALT (alanine aminotransferase): May be elevated if hepatic involvement (metastatic spread) is present.
• ·BUN / CREA: Generally within reference range unless concurrent renal disease or severe dehydration leads to prerenal azotemia.
• ·Total bilirubin (TBIL): Usually within normal limits unless hepatic infiltration is significant.
• ·Calcium: Hypercalcemia may be noted as a paraneoplastic finding [2], though it may resolve with treatment.
• ·B12 (cobalamin) and folate: Deficiencies are common in intestinal lymphoma and reflect ileal/jejunal malabsorption; measurement is clinically recommended.
• ·PLT (platelets): Usually within normal range but thrombocytopenia can develop with bone marrow infiltration or disseminated intravascular coagulation (DIC).

Diagnostic imaging:

• ·Abdominal ultrasonography (US): The primary imaging modality. Key findings include mesenteric lymphadenomegaly (enlarged, hypoechoic lymph nodes), loss of normal intestinal wall layering (particularly muscularis propria effacement), intestinal wall thickening, and hypoechoic mass lesions. Large cell lymphoma tends to produce more severe ultrasonographic disruption than LGAL.
• ·Radiography: May reveal a mass effect, loss of abdominal detail (ascites), or organomegaly.

Cytology: Fine-needle aspirate (FNA) of enlarged mesenteric lymph nodes (ultrasound-guided) or intestinal masses is often diagnostic for HGAL, as the large, pleomorphic neoplastic lymphocytes are readily identified cytologically [1]. This is a critical advantage over LGAL, which requires histology.

Histopathology and immunohistochemistry (IHC): Full-thickness intestinal biopsy (via laparotomy or laparoscopy) with IHC for CD3 (T-cell marker) and CD20/CD79a (B-cell markers) confirms immunophenotype and grade when cytology is equivocal or additional characterization is needed [1][3].

PARR (PCR for antigen receptor rearrangement): Clonality testing can support diagnosis when morphology alone is insufficient to distinguish reactive from neoplastic lymphoproliferation.

Retroviral testing: FeLV and FIV testing is recommended as part of baseline workup, although HGAL is predominantly FeLV-negative.

Treatment of large cell alimentary lymphoma is predominantly systemic, given the disseminated nature of the disease. Response rates and duration of remission are substantially inferior to those seen in LGAL.

Multi-agent chemotherapy (CHOP-based protocols): The standard of care for large cell (high-grade) lymphoma in cats is combination chemotherapy modeled on the CHOP protocol (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisolone). This protocol is associated with higher response rates than single-agent protocols for HGAL.

Single-agent or modified protocols:

• ·Doxorubicin-based single-agent therapy: Doxorubicin alone or in combination with other agents has been used in cats unable to tolerate full CHOP.
• ·COP protocol (cyclophosphamide, vincristine, prednisolone): Used when doxorubicin is contraindicated (e.g., pre-existing cardiac disease).
• ·Prednisolone monotherapy: Rarely achieves meaningful remission in large cell disease; primarily a palliative option where chemotherapy is declined or not tolerated.

Supportive and ancillary care:

• ·Nutritional support: Esophagostomy or gastrostomy tube feeding may be required in severely anorexic or cachectic cats to maintain adequate caloric intake and support treatment tolerance.
• ·Cobalamin (B12) supplementation: Parenteral cyanocobalamin supplementation is indicated when hypocobalaminemia is documented, as deficiency impairs mucosal recovery and overall condition.
• ·Anti-emetics: Maropitant, ondansetron, or metoclopramide to control chemotherapy-related and disease-related vomiting.
• ·Fluid therapy: Intravenous fluids to correct dehydration, electrolyte imbalances (hypokalemia, hyponatremia), and support renal perfusion during chemotherapy.
• ·Gastroprotectants: Omeprazole or sucralfate may be used to manage gastrointestinal mucosal injury.
• ·Antibiotics: Prophylactic or therapeutic antibiotics (e.g., amoxicillin-clavulanate) may be used when secondary bacterial translocation or neutropenic sepsis is a concern.

Surgical intervention: Surgery is generally not curative for diffuse alimentary lymphoma but may be indicated for focal obstructive lesions or perforation. Surgical debulking alone does not alter the course of systemic disease.

Management of paraneoplastic complications: Hypercalcemia should be addressed with IV fluid diuresis and, if severe, bisphosphonates. Corticosteroids (prednisolone), already part of chemotherapy protocols, also help reduce paraneoplastic hypercalcemia [2].

The prognosis for feline large cell (high-grade) alimentary lymphoma is significantly worse than that for low-grade disease, and mesenteric lymph node involvement is a marker of advanced disease.

Overall prognosis: Guarded to poor. Large cell alimentary lymphoma carries a substantially inferior prognosis compared to LGAL, for which median survival times exceeding 20–27 months have been reported with appropriate therapy [3]. In contrast, HGAL is associated with markedly shorter survival times regardless of treatment approach.

Response to chemotherapy: While some cats with HGAL achieve complete or partial remission with CHOP-based protocols, remission duration is typically short, measured in weeks to a few months. A subset of cats does not respond to chemotherapy at all.

Mortality context: Large cell alimentary lymphoma is considered a high-mortality disease. Based on the clinical literature, cats with HGAL have a median survival on the order of weeks to a few months with treatment, and days to weeks without treatment. The disease is ultimately fatal in virtually all affected cats.

Comparison with LGAL: The marked contrast in survival between subtypes underscores the clinical importance of accurate grading. LGAL cases achieving remission with chlorambucil and prednisolone had prolonged survival [3], whereas HGAL does not demonstrate comparable responses. Cytological diagnosis of HGAL from mesenteric lymph node aspirates (without requiring biopsy) allows earlier initiation of therapy [1], which may modestly improve outcomes.

Paraneoplastic complications and prognosis: Cats presenting with paraneoplastic syndromes such as marked eosinophilia, basophilia, and hypercalcemia [2] often have advanced disease, and these findings should temper prognostic optimism.

Limitations: The referenced literature does not provide explicit median survival statistics specifically for the mesenteric lymph node large cell subtype as an isolated cohort; precise survival figures are extrapolated from broader HGAL outcome data in the veterinary oncology literature. Clinicians should counsel owners that long-term remission is uncommon and that quality of life assessment is central to treatment decision-making.

There are currently no established preventive measures specifically proven to prevent feline large cell alimentary lymphoma.

Retroviral prevention: Since FeLV infection has historically been associated with lymphoma risk in cats, maintaining FeLV vaccination protocols and testing/quarantine of new cats may reduce overall lymphoma risk, although HGAL of the alimentary form occurs predominantly in FeLV-negative cats.

Management of chronic gastrointestinal inflammation: Given the hypothesized link between chronic IBD and eventual lymphomatous transformation, prompt diagnosis and appropriate long-term management of feline IBD may theoretically reduce risk, though a direct causal relationship and evidence for prevention through IBD management have not been established in peer-reviewed literature.

Routine health screening: Regular veterinary examinations including abdominal palpation and periodic blood work in middle-aged to older cats may facilitate earlier detection of lymphoma, potentially at a lower-grade stage where treatment outcomes are more favorable [1][3].

Diet and environment: No specific dietary or environmental modifications have been demonstrated to prevent alimentary lymphoma in cats. Minimizing chronic antigenic stimulation of the gastrointestinal mucosa through appropriate parasite control and dietary management is generally advisable for overall gastrointestinal health.

Genetic susceptibility: No breed-specific prevention strategies are currently available, though certain breeds (e.g., Siamese) may have elevated lymphoma risk.